Quest Diagnostics Inc. logo

Quest Diagnostics Inc. (DGX)

Market Closed
20 Jul, 20:00
NYSE NYSE
$
207. 66
-3.02
-1.4334%
$
22.34B Market Cap
20.12 P/E Ratio
5.98% Div Yield
625,781 Volume
8.71 Eps
$ 210.68
Previous Close
Add Transaction
Day Range
205.61 211
Year Range
165.3 219.2
Want to track DGX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 5 months ago
Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands

Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands

Quest Diagnostics gets reaffirmed as a buy for the 3rd time in a row. Key bullish drivers include organic growth, macro demand, strong profit margins among peers, and an investment-grade view from Fitch and S&P. The key peer in the US of Labcorp, it is also a proven dividend grower.

Seekingalpha | 5 months ago
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 6 months ago
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 6 months ago
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?

Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 6 months ago
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why

Quest Diagnostics (DGX) Upgraded to Buy: Here's Why

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 6 months ago
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?

Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?

DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.

Zacks | 6 months ago
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.

Zacks | 6 months ago
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock

Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 7 months ago
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 7 months ago
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term

Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 7 months ago
Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?

Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?

DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.

Zacks | 7 months ago
Loading...
Load More